Glenmark Pharmaceuticals Limited

rs,

May 19, 2023 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of Indi

₹ 129,901

Glenmark Group, today Leading Integrated Research-led Global Consolidated revenues in FY23: ₹ 129,901 mn 14th largest1 and amongst the fastest growing in the Indian market 15th largest2 generic comp

10 million

neric company by prescriptions filled in the USA 5th largest3 Indian generic company in Europe ~10 million4 COVID patients globally prescribed with FabiFlu® (favipiravir) End-to-end R&D capabilities: API

55%

diversified formulations business built organically with commercial presence in 80+ countries ~55% contribution to revenue coming from branded markets5 Dermatology, Respiratory, Oncology: clear f

82.84%

th branded, generics, and OTC segments in therapy areas of Dermatology, Respiratory and Oncology (82.84% subsidiary) Focused on manufacturing and marketing of API products across all major markets glob

100%

sed on manufacturing and marketing of API products across all major markets globally (US based; 100% subsidiary) Innovation biotech company focused on development of novel biological molecules as po

3 million

year 2025** Zero waste to landfill at all our plant locations by the year 2027 Aspire to impact 3 million lives by 2025 Deepen global presence and deliver quality affordable in new markets Continue focu

Rs. 33,737

emissions only ** for GPL only (excluding GLS) 5 Q4 FY23 Snapshot  Revenues from Operations at Rs. 33,737 Mn with a growth of 11.7% YoY  EBITDA of Rs. 6,050 Mn with EBITDA margin of 17.9% “We delivered y

11.7%

(excluding GLS) 5 Q4 FY23 Snapshot  Revenues from Operations at Rs. 33,737 Mn with a growth of 11.7% YoY  EBITDA of Rs. 6,050 Mn with EBITDA margin of 17.9% “We delivered yet another year of robus

Rs. 6,050

FY23 Snapshot  Revenues from Operations at Rs. 33,737 Mn with a growth of 11.7% YoY  EBITDA of Rs. 6,050 Mn with EBITDA margin of 17.9% “We delivered yet another year of robust performance, despite the

17.9%

rations at Rs. 33,737 Mn with a growth of 11.7% YoY  EBITDA of Rs. 6,050 Mn with EBITDA margin of 17.9% “We delivered yet another year of robust performance, despite the challenging global macro-econo

25.1%

henomenally  Consolidated Revenue of Rs. 33,737 Mn; growth of 11.7% YoY  ROW Business growth of 25.1%  Europe Business growth of 22.3% well. We continued to make headway in launching Ryaltris®, our

Notes

2

Notes

1. As per IQVIA MAT March 2023 FY23 FY22 North America 8 ANDA approvals and 8 launches in FY23 FY23 24% 8 ANDA filings in FY23; 10-12 filings targeted in FY24 Revenue (INR Mn) YoY: 15.3% QoQ: 1.6% 8,507 8,373 7,378 Key Highlights  Notable approvals include: Sodium Phenylbutyrate Tablets USP, 500 mg; Nicardipine Hydrochloride Capsules; Clindamycin Hydrochloride Capsules  Notable launches include Ezetimibe Tablets USP; Abiraterone Acetate Tablets USP, 500 mg; Fingolimod Capsules, 0.5 mg; Sodium Phenylbutyrate Tablets USP, 500 mg; Nicardipine Hydrochloride Capsules  One of the first companies to launch generic Teriflunomide (Aubagio®) Tablets  Announced an exclusive distribution agreement with Cediprof for U.S. FDA-approved Mixed Amphetamines Immediate-Release Tablets  Marketing portfolio through March 31, 2023 consists of 183 generic products authorized for distribution in the U.S. market Q4 FY23 Q4 FY22 Q3 FY23 31,041 30,366 YoY: 2.2% 15 FY23 FY22 Europe Revenue of USD 225+ Mn in F

Notes

1. As per IQVIA MAT March 2023 2. Top 10 products within “R1A1 – Nasal Corticosteroids without Anti Infectives” category as per IQVIA + Ryaltris® FY23 FY22 API business - Glenmark Life Sciences 11% FY23 Consolidated sales (including captive sales) growth of 21% YoY CDMO revenue grew by 30% YoY in Q4 FY23 Revenue – External Sales (INR Mn) YoY: 16.7% QoQ: 2.0% 3,831 3,756 3,283 Key Highlights  Revenues from operations including captive sales were Rs. 6,213 Mn recording a YoY growth of 21%  Generic API revenues in Q4 FY23 increased by 10.4% QoQ and by 15.5% YoY Q4 FY23 Q4 FY22 Q3 FY23 14,582 YoY: 14.7% 12,709 CDMO revenues in Q4 FY23 doubled sequentially Steady growth momentum across regulated as well as emerging markets Total cumulative 468 DMF / CEP filings across the globe as on March 31, 2023    18 FY23 FY22 Respiratory Strategy – Creating Global Scale       As of Q4 FY23, marketing applications for Ryaltris® have been submitted in more than 70 countries, the product has be